A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.
作者： Vivek Roy , Barbara A. Pockaj , Jacob B. Allred , Heidi Apsey , Donald W. Northfelt
DOI: 10.1097/COC.0B013E318256F619
关键词:
摘要: Objective:We conducted a multicenter phase II trial to assess the efficacy and toxicity of docetaxel carboplatin combination as neoadjuvant therapy for stage or III breast cancer (BC).Methods:Patients received 75 mg/m2 AUC 6 on day 1 followed by pegfilgrastim o
elsevier.com
wkhealth.com参考文章(27)
Z Baloch, A J Prestipino, U L Seinige, B A Mason, D M Sataloff, C P Lieber, Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. Journal of The American College of Surgeons. ,vol. 180, pp. 297- 306 ,(1995)
M E O'Brien, D C Talbot, I E Smith, Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. Journal of Clinical Oncology. ,vol. 11, pp. 2112- 2117 ,(1993) , 10.1200/JCO.1993.11.11.2112
Aman U. Buzdar, S. Eva Singletary, Richard L. Theriault, Daniel J. Booser, Vicente Valero, Nuhad Ibrahim, Terry L. Smith, Lina Asmar, Debra Frye, Nikki Manuel, Shu-Wan Kau, Marsha McNeese, Eric Strom, Kelly Hunt, Frederick Ames, Gabriel N. Hortobagyi, Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 3412- 3417 ,(1999) , 10.1200/JCO.1999.17.11.3412
Roland Reitsamer, Florentia Peintinger, Eva Prokop, Wolfgang Hitzl, Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anti-Cancer Drugs. ,vol. 16, pp. 867- 870 ,(2005) , 10.1097/01.CAD.0000173475.59616.B4
Katrina R. Bauer, Monica Brown, Rosemary D. Cress, Carol A. Parise, Vincent Caggiano, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. ,vol. 109, pp. 1721- 1728 ,(2007) , 10.1002/CNCR.22618
Chafika Mazouni, Florentia Peintinger, Shu Wan-Kau, Fabrice Andre, Ana M. Gonzalez-Angulo, W. Fraser Symmans, Funda Meric-Bernstam, Vicente Valero, Gabriel N. Hortobagyi, Lajos Pusztai, Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome Journal of Clinical Oncology. ,vol. 25, pp. 2650- 2655 ,(2007) , 10.1200/JCO.2006.08.2271
Edith A. Perez, Vera J. Suman, Tom R. Fitch, James A. Mailliard, James N. Ingle, John T. Cole, Michael H. Veeder, Patrick J. Flynn, Daniel J. Walsh, Ferdinand K. Addo, A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932 Oncology. ,vol. 69, pp. 117- 121 ,(2005) , 10.1159/000087813
Anamitra Bhattacharyya, Uy S. Ear, Beverly H. Koller, Ralph R. Weichselbaum, Douglas K. Bishop, The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin Journal of Biological Chemistry. ,vol. 275, pp. 23899- 23903 ,(2000) , 10.1074/JBC.C000276200
Torsten O Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, Chad Livasy, Dave Cowan, Lynn Dressler, Lars A Akslen, Joseph Ragaz, Allen M Gown, C Blake Gilks, Matt van de Rijn, Charles M Perou, None, Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma Clinical Cancer Research. ,vol. 10, pp. 5367- 5374 ,(2004) , 10.1158/1078-0432.CCR-04-0220
Ian K. Komenaka, Chiu‐Hsieh Hsu, Maria Elena Martinez, Marcia E. Bouton, Boo Ghee Low, Jason A. Salganick, Jesse Nodora, Michael L. Hibbard, Chandra Jha, Preoperative Chemotherapy for Operable Breast Cancer Is Associated with Better Compliance with Adjuvant Therapy in Matched Stage II and IIIA Patients Oncologist. ,vol. 16, pp. 742- 751 ,(2011) , 10.1634/THEONCOLOGIST.2010-0266